Campus Cañar
URI permanente para esta comunidad
Examinar
Examinando Campus Cañar por Asesores "Cajamarca Naula, Susana"
Mostrando 1 - 1 de 1
Resultados por página
Opciones de ordenación
- ÍtemAcceso AbiertoInmunidad desarrollada de la vacuna Pfizer para sars-cov-2 implementadas en el país. Una revisión sistemática .(Universidad Católica de Cuenca, 2022-07-01) Chima Alvacora, Jenny Carolina; Cajamarca Naula, Susana; 035016197-2Introduction: The world has faced several pandemics, but undoubtedly the appearance of Covid-19 made a difference in human existence due to its high mortality rate. To deal with it, the creation of a vaccine was one of the most emerging ways and it was achieved in a record time with the appearance of the Pfizer-BioNTech vaccine. It has demonstrated an efficacy of 95% in the creation of coronavirus antibodies. Objective: To systematize the available scientific evidence on the Pfizer vaccine immunity for Sars-cov-2 held in the country. Method: The study was conducted using the prism method and the application of eligibility criteria (English-Spanish language, use of keywords, publications 2018-2022), the application of the PICO method is also added for choosing studies and the digital libraries searches. Results: The research studies allowed the creation of the following categories of analysis: Covid-19 vaccination, Pfizer-BioNTech vaccine, generation of Covid-19 antibodies, Pfizer vaccine efficacy, and Pfizer-BioNTech vaccine flexibility. Conclusion: The Pfizer/BioNTech vaccine immunization against the Sars-CoV-2 virus has produced an efficacy in reducing the risk of severe disease and possible hospitalization in patients in an 89.2%, 91.6% reduction of the ICU wards and 87.8% mortality. All this has been achieved thanks to the vaccine’s flexibility and its high effectiveness. Keywords: immunity, vaccine, sars-cov-2, implementation, population